Managing inflammation for COPD and asthma GSK has led in pulmonary disease treatment for 50+ years, advancing the genetics of respiratory illness.

Sep 17, 2025 · GSK plc (LSE/NYSE: GSK) today announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.

6 days ago · GSK plc (LSE/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW’26, the 9th Conference of the …

At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company …

Trade marks are owned by or licensed to the GSK group of companies.</p>\n<p>GSK plc. Registered in England and Wales No. 3888792.</p>\n<p>Registered office: 79 New Oxford Street, London.

Disaster response - Contact our US Response Center online if you need help accessing your GSK medicines during a natural disaster. Patient Assistance Programs - We are committed to helping …

Unfortunately, we cannot provide comprehensive information about our products here, in compliance with regulations. If you are a healthcare professional, you can access more product information on …

GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs.

Life at GSK We are transforming our culture to create an environment where individuals and teams are inspired to be ambitious for patients

The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA site dedicated to smallpox vaccine production since 1882. Today, our …